Research Article

Metabolic Characteristics In The Subgroups Of Polycystic Ovary Syndrome

Volume: 44 Number: 4 December 31, 2022
EN

Metabolic Characteristics In The Subgroups Of Polycystic Ovary Syndrome

Abstract

Aim: Polycystic ovary syndrome (PCOS) is a heterogenous disease that is characterized with chronic anovulation, menstrual irregularities and hyperandrogenism. In the present study we aimed to compare the metabolic features of PCOS'subgroups based on revised Rotterdam diagnostic criterias.
Materials and Methods: Ninety-five women with PCOS were enrolled into the study and divided into four groups. Group 1; oligomenorrhea and/or anovulation with biochemical hyperandrogenemia and/or hyperandrogenism, group 2; biochemical hyperandrogenemia and/or hyperandrogenism with polycystic ovaries, group 3; oligomenorrhea and/or anovulation with polycystic ovaries and group 4; polycystic ovaries with oligomenorrhea and/or anovulation with biochemical hyperandrogenaemia and/or hyperandrogenism. Body mass indeces (kg/m2) and waist to hip ratios were calculated in all study patients. Fasting glucose, lipid levels, kidney and liver function tests were measured after 12 hours fasting. Oral glucose tolerance test (OGTT) was performed to evaluate the responses of glucose and insülin. Hormone levels were measured during the follicular phase of the menstrual cycle. Adrenocorticotrophic hormone (ACTH) (0.5 mg Synacthen IM) and gonadotrophin-releasing hormone agonist (buserelin) tests were performed in order to evaluate adrenal and ovarian hyperandrogenemia. Ovarian ultrasonography was performed on all study patients to define PCO morphology.
Results: The frequency of the classical PCOS phenotype was higher than the non-classical PCOS phenotype (74.7% and 25.2%, respectively). Body mass indexes, waist-hip ratios, serum total, LDL and HDL-cholesterol levels were similar in all groups. Serum triglyceride levels were found to be significantly lower in group 2 compared to other groups (p< 0.01). Peak insulin and AUC insulin levels were significantly lower in group 2 (p< 0.05). The prevalence of impaired fasting glucose and impaired glucose tolerance was similar in all groups. Free testosterone and androstenedione levels were significantly lower in group 3 compared to group 4.
Conclusion: Metabolic disturbances of patients with PCOS without hyperandrogenism (OA+PCO; group 3) were similar to the classical PCOS groups contrary to the expectations. The metabolic disturbances found in patients with PCOS without menstrual dysfunction (HA+PCO; group 2) were found to be milder in terms of lipid levels and insulin resistance. These findings support that newly developed HA+PCO and OA+PCO groups are the part of wide PCOS spectrum and also it supports that PCO morphology is one of the diagnostic criterias of PCOS.

Keywords

Supporting Institution

YOK

Project Number

YOK

References

  1. 1. Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol 2018;17(1):37. doi: 10.1186/s12933-018-0680-5.
  2. 2. Trikudanathan S. Polycystic ovarian syndrome. Med Clin North Am 2015;99(1):221–35. doi: 10.1016/j.mcna.2014.09.003.
  3. 3. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
  4. 4. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36 Suppl 1(Suppl 1):S67-74. doi: 10.2337/dc13-S067.
  5. 5. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006; 154: 141-5. doi: 10.1530/eje.1.02058.
  6. 6. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Horowtiz BN, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers 2016;2:16057. doi: 10.1038/nrdp.2016.57.
  7. 7. Zore T, Joshi NV, Lizneva D, Azziz R. Polycystic Ovarian Syndrome: Long-Term Health Consequences. Semin Reprod Med 2017;35(3):271–81. doi: 10.1055/s-0037-1603096.
  8. 8. Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS. Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Fertil Steril. 2007; 88: 727-9. doi: 10.1016/j.fertnstert.2006.11.149.

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Research Article

Publication Date

December 31, 2022

Submission Date

December 12, 2022

Acceptance Date

December 27, 2022

Published in Issue

Year 2022 Volume: 44 Number: 4

AMA
1.Yılmaz M, Keleştemur F. Metabolic Characteristics In The Subgroups Of Polycystic Ovary Syndrome. CMJ. 2022;44(4):397-403. doi:10.7197/cmj.1216549